BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 75 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $21,533,000 | +61.3% | 3,401,744 | +12.4% | 0.00% | +33.3% |
Q3 2016 | $13,352,000 | +64.9% | 3,027,595 | +6.2% | 0.00% | +50.0% |
Q2 2016 | $8,095,000 | +2.1% | 2,850,238 | +1.8% | 0.00% | 0.0% |
Q1 2016 | $7,926,000 | -72.5% | 2,800,786 | +0.4% | 0.00% | -71.4% |
Q4 2015 | $28,789,000 | -13.3% | 2,789,584 | -4.2% | 0.01% | -22.2% |
Q3 2015 | $33,194,000 | -21.3% | 2,911,728 | +3.1% | 0.01% | -10.0% |
Q2 2015 | $42,158,000 | +63.2% | 2,823,718 | -1.3% | 0.01% | +66.7% |
Q1 2015 | $25,834,000 | -24.2% | 2,860,900 | +2.0% | 0.01% | -25.0% |
Q4 2014 | $34,103,000 | +36.8% | 2,804,541 | +10.1% | 0.01% | +14.3% |
Q3 2014 | $24,921,000 | -23.6% | 2,548,170 | -0.4% | 0.01% | -22.2% |
Q2 2014 | $32,616,000 | +243.3% | 2,558,112 | +184.8% | 0.01% | +200.0% |
Q1 2014 | $9,502,000 | +49.8% | 898,132 | +7.6% | 0.00% | +50.0% |
Q4 2013 | $6,344,000 | +487.4% | 834,789 | +462.8% | 0.00% | – |
Q3 2013 | $1,080,000 | +462.5% | 148,335 | +19.6% | 0.00% | – |
Q2 2013 | $192,000 | – | 123,985 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |